Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

Inclusion Criteria: * Capable of giving signed informed consent (as described in the protocol), which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. * Participants must be 18 to 75 years old (inclusive) at Screening (signing the ICF). * Diagnosis of asthma, as defined by the National Asthma Education and Prevention Program, at least 12 weeks prior to Screening. * Participants who are stable on their chronic asthma treatment regimen for at least 4 weeks prior to Screening. * Pre-bronchodilator FEV1 of \>40% and \<85% of predicted value, at Screening. * Participants with FEV1 reversibility of ≥12% and ≥200 mL within 30 minutes following 360 mcg of albuterol inhalation (via pressurized metered dose inhaler pressurized metered-dose inhaler \[pMDI\]) or equivalent at Screening. * This what you mean: Participants who are currently non-smoking and have not used tobacco smoking or smoked marijuana products, within the past year. * Participants who are able to replace their current regularly scheduled short-acting β2-agonists (SABAs) with a salbutamol/albuterol inhaler for use only on an 'as-needed' basis for the duration of the study. * Participants must be able to discontinue their asthma medications during the Run-in period, and for the remainder of the study. * Participants who can demonstrate the correct use of inhaler device (during the Run-in period and at Randomization visit). * Participants are eligi…